Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

AllurionMeds is designed to address a critical demand from patients: The Weight Must Stay Off

Features Coach Iris, a first-of-its-kind conversational AI behavioral agent for weight loss and maintenance, trained using real-world experience in over 150,000 patients

Compounded GLP-1 program designed to provide long-term behavioral change while addressing weight re-gain and other negative side effects for patients

Expands Allurion’s presence to all 50 states, helping to grow awareness of the mission to end obesity while creating foothold for future product launches

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the launch of AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company’s AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight but muscle and bone mass.

“Feedback from patients is clear; the weight must stay off. Our platform was designed specifically to help patients lose weight and keep it off,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer of Allurion. “AllurionMeds is built around safety, efficacy and, importantly, efficiency. Without affordable medications for weight loss and AI-powered behavior change, we risk bankrupting the US healthcare system.”

The market opportunity for GLP-1s in the United States continues to grow, with expectations that it exceeds $100 billion with 30 million total users by 2030.¹ Recent studies are reporting, however, that 30% of patients discontinue GLP-1 drugs in the first month² with significant muscle mass loss³. These issues, combined with prices in excess of $1,300 per month⁴, will further the obesity epidemic and lead to untenable expense in the US unless access and support is improved for the millions of Americans living with this disease.

Program will utilize AI to address most common GLP-1 concerns, including weight regain

The AllurionMeds GLP-1 program, with support from Coach Iris, will address the most common concerns from patients looking to begin a GLP-1 program. Patients in the program will receive access to the Allurion Connected Scale and Allurion’s GLP-1 companion app. The scale measures not only weight but also muscle and bone mass to ensure that both the quantity and quality of weight loss is being monitored. Previous studies have shown that Allurion’s scale, app and lifestyle modification program in conjunction with the Allurion Balloon have helped patients lose weight while actually gaining muscle mass and helped them keep the weight off in the long-run^5,6.

“We are taking our decade-long experience of treating over 150,000 patients to launch an innovative, AI-native platform designed to solve the problems GLP-1 users face and provide a best-in-class experience,” said Dr. Gaur. “Real-world use of GLP-1s has highlighted three critical issues: poor medication adherence and wrap-around support, muscle and bone mass loss, and untenable cost to the healthcare system. AllurionMeds leverages our existing platform to address all three of these issues by providing 24/7 AI-powered coaching, monitoring of weight, muscle mass and bone mass, and offering high quality and affordable compounded semaglutide delivered at home.”

AllurionMeds partnered with FDA-registered pharmacies to provide safe and financially accessible GLP-1 products available across the US

Together with Coach Iris, patients will receive GLP-1 drugs that are sourced from an FDA-registered 503b facility adherent to Current Good Manufacturing Practice (CGMP) regulations. Every batch has been tested for sterility and potency, among other things, before release.

“Safety and ease of use were paramount to us as we were designing AllurionMeds,” said Brian Conyer, Vice President of Digital Health at Allurion. “After careful evaluation of multiple partners, we selected pharmacies that met our high standards to create an experience that is ‘always on’ through Coach Iris. In the future, we intend to expand the types of GLP-1s available and also offer brand-name versions to provide patients with as many options as possible for their weight loss journey.”

Additionally, with the launch of AllurionMeds, the company has expanded its product offerings to all 50 states in the United Sates. Previously, the company had launched the Virtual Care Suite, its B2B AI product, to obesity management clinics in the United States.

“AllurionMeds further expands our presence in the United States,” said Dr. Gaur. “I believe the relationships we are creating with patients and providers in the United States could benefit future product launches by creating a foothold in the largest obesity market in the world.”

To access AllurionMeds, please visit https://www.allurionmeds.com/.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, Procedure-less™ intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the launch of the compounded GLP-1 program and the potential benefits and costs of such program, including its ability to promote long-term weight maintenance, address common GLP-1 issues and concerns, provide safe and financially accessible products, and gain a foothold in the U.S. for other products. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize its program, including the Allurion Balloon, its VCS platform, and its compounded GLP-1 program, in the United States and abroad, (ii) the timing of, and results from, our clinical studies and trials and submission of such results to regulatory authorities, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the conflict in the Middle East on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the Allurion Program, its VCS platform, and its compounded GLP-1 program (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended), Quarterly Report on Form 10-Q filed on November 13, 2024, and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

¹ https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
² https://www.bcbs.com/about-us/association-news/most-americans-stop-weight-loss-drugs-before-seeing-meaningful-benefit
³ Wilding et al. NEJM. 2021;384:989-1002.
⁴ Hernandez et al. Obesity. 2024;32:472-475.
⁵ Dejeu et al. Clin. Pract. 2024;14:765-778.
⁶ Kosai et al. Obes Surg. 2024;34:3366-3371.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241125630472/en/

Global Media

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com

Investor Contact

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.